Advanced Medical Techniques

Peter Thiel and Jeff Bezos just backed a $3B startup that destroys tumors with sound waves. It’s called HistoSonics, Inc., a US medtech company born out of the University of Michigan - now headquartered in Minnesota - developing a non-invasive cancer therapy powered by focused ultrasound. No scalpels. No radiation. No chemo. Here’s what makes it groundbreaking 👇 ▶ 1. How it works HistoSonics’ device, called Edison, emits pulsed ultrasound waves that create “bubble clouds” inside tissue. These bubbles collapse within microseconds - producing mechanical forces strong enough to destroy tumors at a cellular and subcellular level. ▶ 2. Proof it’s working The tech won FDA approval in late 2023 and is already used by 150+ hospitals, including the Cleveland Clinic. Each system costs about $1.5M, and the company expects $100M+ in revenue this year. ▶ 3. The investors betting big HistoSonics just raised $250 million, led by K5 Global, Wellington Management, and Bezos Expeditions, with Thiel Capital joining as a new investor - valuing the company at around $3 billion. The new funding will help expand treatments for tumors in the breast, prostate, pancreas, and brain. ▶ 4. The next frontier The company aims to scale globally, with European regulatory approval targeted for 2026. Founder Mike Blue calls it “a paradigm shift in how we treat cancer” - replacing invasive surgery with precision sound. And I agree.. it’s a bold vision: A future where tumors are treated with sound instead of surgery. But challenges remain - from long-term safety data to proving this can scale beyond high-end hospitals. Still, if HistoSonics succeeds, it could reshape how oncology looks a decade from now - not by extending life through suffering, but by removing that trade-off entirely. Do you think non-invasive sound therapies could become the new standard in cancer care? #entrepreneurship #healthtech #innovation

💉✨ “New Knee Without Surgery?” – The Truth Behind Germany’s Cartilage Repair Gel Since 2013, Germany has used a collagen-based gel (ChondroFiller/AMIC) to repair worn-out joint cartilage. 👉 It’s not just a quick injection—it requires a minimally invasive keyhole surgery where the gel acts as a scaffold for your body to regrow cartilage. 👉 Social media might call it a “brand-new miracle,” but it’s actually a decade-old technique. 👉 The real breakthroughs today? Injectable, biodegradable hydrogels now in clinical trials—designed to mimic natural cartilage and dissolve as new tissue grows. Yes—Germany has produced an injectable collagen-based gel, originally known as ChondroFiller, designed to help repair damaged joint cartilage in a minimally invasive way. Developed in collaboration with Fraunhofer Institute, it’s been available since 2013 and requires only a brief injection—not full-blown surgery. While posts on social media have recently hyped it as a brand-new breakthrough, the truth is more measured: the gel still involves minor procedures and carries the usual risks of allergic reactions. Current research continues to explore even more advanced, biodegradable cartilage-regenerating gels that mimic natural joint environments and dissolve as new tissue forms. These innovations are still experimental, with promising results in early trials—but they’re not yet ready for everyday clinical use. Would you try regenerative gels instead of joint replacement in the future? 🤔👇 #MedicalMyths #RegenerativeMedicine #CartilageRepair #JointHealth #Orthopedics #Biotech #FutureOfMedicine

Frozen Shoulder Demystified: Diagnosis, Physiotherapy, and Beyond Definition: Progressive pain and stiffness in the glenohumeral joint, limiting motion. Clinical Phases: -Freezing: Pain with gradual stiffness (2-9 months). -Frozen: Stiffness dominates, pain lessens (4-12 months). -Thawing: Gradual motion recovery (5-24 months). Pathology -Inflammation and fibrosis of the joint capsule. -Affects anterosuperior capsule, axillary recess, and coracohumeral ligament. -Results in contracture and reduced joint space. Epidemiology -Prevalence: 2-5% general population, 20% in diabetics. -Predominant in women (70%), ages 35-65. -Risk factors: Diabetes, metabolic syndrome, hypothyroidism, post-surgery/injury. Clinical Presentation -Insidious onset with pain and restricted motion. -Most notable restriction: External rotation. -Difficulty with overhead activities, dressing, grooming. -Night pain and sleep disturbance. Diagnosis -History: Pain, restricted ROM, and triggers. -Physical Exam: Capsular restriction (ER > ABD > IR). -Imaging: MRI shows thickened joint capsule. Treatment Conservative: -Pain relief: NSAIDs, corticosteroid injections. -Physical therapy: Gentle mobilization, stretching. Advanced Cases: -Manipulation under anesthesia. -Arthroscopic capsular release. Prognosis -Self-limiting: 6 months to 3 years. -40% may experience persistent symptoms beyond 3 years. Physical Therapy Management Role & Techniques -Key to recovery; focus on PNF and pain relief. Phase-specific management: -Freezing: Pain-free ROM, gentle mobilization (e.g., pendulum exercises). -Frozen: Joint mobilization, dynamic splinting. -Thawing: Stretch progression, strengthening. Use high-grade mobilizations (posterior glides for external rotation). Stretching -Low-intensity, prolonged stretching for tissue elongation. -Progress based on tolerance. Motor Control Exercises -Improve shoulder motor control (emerging evidence). Patient Education -Emphasize self-limiting nature and importance of home exercise programs (HEP). Progression & Discharge -Based on pain relief, functional gains, and satisfaction. -Discharge when motion plateaus and pain reduces. Medical Interventions Corticosteroid Injections -Effective for short-term relief (4-6 weeks). -Combine with physical therapy for best results. -Contraindications: Infection, coagulopathy, uncontrolled diabetes. Manipulation Under Anesthesia (MUA) -Effective for persistent symptoms after 6 months. -Risks: Dislocation, fracture, nerve injury. Arthroscopic Capsular Release -Indicated for severe cases >6 months. -Controlled release minimizes complications. Other Treatments -NSAIDs: Limited evidence. -Oral Steroids: Short-term relief; not routine. -Hydrodilatation: Expands capsule; mixed evidence. -Suprascapular Nerve Blocks: Temporary relief; needs validation. Outcome Measures -Tools: SPADI, DASH, ASES, SST, NPRS, VAS. References https://lnkd.in/dp8s-z7F https://lnkd.in/d6dumHSp

Posted with informed patient consent. This surgical content is shared solely for educational purposes.  Educational purposes. Together with Yoaav Krauthammer Krauthammer and our outstanding team at Deer Valley, we successfully performed the second ever robotic hybrid ablation for inappropriate sinus tachycardia (IST) at our DV Location. This marks a significant advancement in the procedural treatment of IST. IST is a complex, often underdiagnosed condition characterized by a persistently elevated heart rate (resting >100 bpm, 24-hour average >90 bpm) accompanied by symptoms like palpitations, dizziness, and reduced exercise tolerance. Standard therapies, beta blockers, ivabradine, and catheter ablation frequently produce suboptimal outcomes, with high recurrence rates and procedural complications. Our approach combined: • Robotic-assisted thoracoscopic access using the da Vinci Xi system • Direct pericardial visualization for enhanced precision and safety • Electrophysiological mapping using the Abbott HD Grid system • Targeted ablation of the sinoatrial node region based on earliest activation patterns Compared to traditional video-assisted thoracoscopic surgery (VATS), robotic-enhanced hybrid ablation offers superior visualization, access, and procedural control, reducing potential risks and improving operator ergonomics. This case demonstrates the potential of robotic hybrid approaches to redefine IST management, especially in patients with refractory disease or limited response to conventional treatments. Proud of our team’s commitment to pushing the boundaries of what’s possible in rhythm surgery. Follow Zain Khalpey, MD, PhD, FACS for more on Ai & Healthcare. #RoboticSurgery #HybridAblation #Electrophysiology #InappropriateSinusTachycardia #IST #CardiacSurgery #CardiothoracicSurgery #MinimallyInvasiveSurgery #ArrhythmiaManagement #HeartRhythm #MedicalInnovation #RoboticAssistedSurgery #Cardiology #EPCommunity #SurgicalInnovation #AdvancedMapping #SinusNodeAblation #daVinciSurgery #FutureOfSurgery #RoboticCardiacCare

Terrible bicondylar tibial plateau fracture with joint comminution. These are bad injuries, with risk of compartment syndrome, wound complications, infection, and post traumatic arthritis. Studies show about 30% risk of complications. This patient had a fasciotomy and external fixation placed. Then definitive surgery 2 days later. Fracture was fixed and wounds were closed. You can see the joint was pretty smashed. It was fixed as best as possible, but it’s hard to make these perfect when there’s so much joint comminution. The lateral meniscus was torn which was fixed as well. And dual plate fixation for medial and lateral sides. ❗️The goal of surgery is to achieve a stable straight knee, and avoid complications (wound healing and infection). While many develope radiographic arthritis, most don’t need a knee replacement. ❗️Studies show the risk of total knee arthroplasty at 10 years post injury is about 7% (5 times higher than a matched cohort). So not as high as some people think, but not insignificant. This one has some radiographic evidence of post traumatic arthritis, which is expected given the initial injury. But one year later patient has minimal symptoms and great range of motion. Used with patient permission #orthotrauma #orthopaedics #orthopedics #ortho #fracture #bone #tibialplateau #knee #tibia

This post is intended for a U.S. audience. Fantastic news from the plenary hall at ASCO! AstraZeneca presented promising results from THREE highly anticipated Phase III trials in breast cancer and gastric/GEJ cancer. We are in a transformation in cancer care, moving away from a one-size-fits-all approach to personalized treatments. Here is what today’s news means for patients: SERENA-6 Phase III trial in 1st-line advanced HR-positive breast cancer with emergent ESR1 tumor mutation: → A new study revealed that instead of waiting for scans to indicate that advanced breast cancer is growing, early signs of drug resistance can be detected. → Researchers achieved this by using a blood test to identify ESR1 mutations in cancer cells, which enable the tumors to resist standard treatments. → This early detection allowed patients to be switched to a different treatment in combination with a CDK4/6 inhibitor. This combination therapy reduced risk of progression or death by 56%allowing patients to have more than an extra year without deteriorating quality of life. MATTERHORN Phase III trial in resectable, early-stage and locally advanced gastric/GEJ: → Trial results begin a new wave of growth for bringing novel treatments to early stages where the chance for cure is highest. → MATTERHORN is the FIRST and ONLY immunotherapy regimen to demonstrate statistically significant and clinically meaningful improvement in event-free survival in this setting. → The immunotherapy regimen demonstrated a 29% reduction in risk of disease progression, recurrence, or death compared to chemo alone. → Over 67% of patients in the trial were event-free at two years. DESTINY-Breast09 Phase III trial in 1st-line HER2-positive metastatic breast cancer: → A late-breaking addition, this trial is the first in over a decade to demonstrate improved outcomes in the 1st-line setting for a broad population of patients with HER2-positive metastatic breast cancer. → Our treatment, developed with our partners at Daiichi Sankyo, plus pertuzumab as 1st-line treatment reduced risk of disease progression or death by 44%. → The median progression-free survival was more than three years, a HUGE win given that patients often progress within two years of starting 1st-line treatment. The studies are innovative and the data is impressive. But what really matters to my team is the potential to deliver more hope to thousands of patients in need of better options than the current standards of care. The feeling of being at ASCO with the oncology community and seeing the impact we’re making – there’s nothing like it. And I’m proud that we’re accelerating the possible to eliminate cancer as a cause of death. 👉 Read more here: https://bit.ly/asco-2025

We have seen prior studies highlight the significant association between sagittal alignment and patient reported outcome measures (PROMS) among adult spinal deformity patients, particularly the C7 SVA and PI-LL mismatch and their influence on patient related outcome measures. Recently, however, there has been an increased focus on incorporating measures that account for the cranium and lower extremities to assess total body sagittal alignment. Thus, the cranial sagittal vertical axis (CrSVA) has been used as a novel parameter to measure the horizontal distance to the vertical plumb line from the nasion-inion midpoint to reference points at the sacrum, hip, knee, and ankle. Preliminary analyses have shown its significance its association with preoperative PROMS, but there’s a scarcity of data on how this parameter correlates with other measures of global alignment, especially at the 2yr postoperative time point. In our newly published study, we validated the CrSVA to be a significant driver of PROMS with the CrSVA to the hip a stronger predictor than the C7 SVA at 2yrs postop. Thus, we recommend the CrSVA, particularly the position of the cranium relative to the hips, as one of the standard postoperative standard sagittal alignment goals for ASD patients. Link to full study: https://lnkd.in/gYfGnZa6 Sarthak Mohanty Fthi M. Hassan, MPH Nathan J. Lee, MD Zeeshan Sardar Ron Lehman, MD #spinesurgery #spinedeformity #alignment #outcomes #orthopedicsurgery #neurosurgery

John couldn't lift a spoon to his mouth. Harvard engineers changed that with a vest and a foot pedal. No surgery. No implants. Just technology that learns how he moves. The breakthrough that changes everything: ↳ 94% accuracy reading intentions ↳ Effort reduced by one-third ↳ 9 users tested: 5 stroke survivors, 4 with ALS ↳ Zero invasive procedures Think about that. As ALS advanced, John lost the ability to feed himself. Every meal required help. Every bite reminded him of what he'd lost. Then he reached out to Harvard's engineering team with one request: Help me eat alone again. While medicine chases cures, these engineers built companionship. A sensor-loaded vest with an inflatable balloon under the arm. Machine learning watches movement patterns. Predicts intentions. Provides support exactly when needed. John's solution was beautifully simple: Press a foot button. The vest inflates. His arm lifts. He feeds himself. Traditional Assistive Reality: ↳ Rigid exoskeletons ↳ Generic movements ↳ $50,000+ costs ↳ Fighting your body Harvard's Approach: ↳ Soft adaptive support ↳ Personalised patterns ↳ Future home use ↳ Working with you But here's what stopped me cold: This technology doesn't try to cure. It companions. For stroke survivors: rehabilitation accelerated. For ALS patients: independence extended. Not about fixing what's broken. About supporting what remains. The vest learns each user's unique patterns. Distinguishes shoulder movements with 94% accuracy. Expands range in shoulders, elbows, wrists. No more compensatory leaning or twisting. Just natural movement, gently assisted. John proved what matters most: A spoon lifted to his own mouth. Dignity restored with each meal. Autonomy measured in small, profound victories. The Multiplication Effect: 1 user = concept proven 100 devices = care transformed 10,000 deployed = independence preserved At scale = disability redefined Consider the numbers: 450,000 people with ALS globally. 15 million strokes annually. 80% facing upper limb challenges. Millions who could keep feeding themselves. Embracing loved ones. Creating. Contributing. Massachusetts General Hospital validated results. National Science Foundation funds home deployment. From lab to life. John didn't just test a device. He defined its purpose. His simple request—help me eat alone—became breakthrough engineering. His persistence now helps millions. The future of assistive technology isn't replacing human function. It's preserving human dignity through intelligent support. Follow me, Dr. Martha Boeckenfeld for innovations that honour what makes us human. ♻️ Share to bring hope to millions facing motor challenges.

Last month, a team of scientists and physicians achieved something extraordinary: they developed and delivered the first-ever personalized #CRISPR therapy to treat an infant with a life-threatening #raredisease — in just six months. A one-letter change in the baby’s DNA was corrected using a custom-built gene editor. The child, who was once facing the prospect of a liver transplant, is now steadily improving. It’s a powerful example of what’s becoming possible at the intersection of #science and #technology, urgency and purposeful ambition. And this isn’t an isolated win. Across labs, clinics, and companies, CRISPR is being used as a therapeutic modality to correct inherited disorders, engineer immune cells, disable viral DNA, and even edit entire chromosomes. New gene-editing systems—like TIGR-Tas, unveiled earlier this year—are expanding what’s possible in tissues or conditions where current tools fall short. Clinical results are emerging fast—and the pace of #innovation is only picking up. At Recursion, we’re also applying #geneediting tools like CRISPR beyond therapeutics—using the technology as a tool to better understand #biology at scale. By systematically “knocking out” thousands of individual genes and measuring how those changes affect cell behavior, we’re generating large, structured datasets that feed directly into #AI models. This is helping us uncover new biological relationships and power #drugdiscovery in ways that were previously unimaginable. What ties all of this together is a commitment to applying game-changing #innovation in service of real, urgent human needs. It signals a much-needed mindset shift in #healthcare and #biopharma: to move faster, think bigger, and tackle challenges once considered out of reach—and to truly deliver on the promise of #precisionmedicine. And we’re seeing this ambition in many other areas as well – just last week, for example, GRAIL announced more promising than ever performance stats for its #Galleri blood test for the early detection of 50+ types of #cancer. There’s still work ahead to ensure breakthroughs translate into broad, equitable impact. But this moment – this momentum – is worth pausing to recognize. We’re no longer just imagining a future where science works smarter and faster for patients. We’re building it.

Last week, I read an article in NZZ about artificial intelligence and personalized cancer therapy, a topic that highlights both the long-standing ambitions and the current realities of precision medicine. For decades, precision medicine has promised treatments tailored to each individual. In reality, medicine has often had to rely on averages: what works for many, rather than what works for this person. In cancer care, this gap can be especially painful. Patients may endure therapies that ultimately do little good, while causing significant side effects. Researchers in Zurich are now exploring a different path. Instead of starting only with genetic data, they look at how a patient’s own cancer cells behave. Thousands of microscope images are generated after exposing these cells to different drugs. AI systems analyze these images and learn patterns that even trained experts cannot easily see. The result is not a single “magic answer,” but a ranked list of therapies that are most likely to work for that specific patient. What stands out is not only the technology, but the mindset behind it. This is not about replacing doctors with algorithms. It’s about augmenting human judgment with better tools. It’s about reducing guesswork. It’s about acknowledging how different each human body truly is. At the same time, the article is refreshingly honest. These approaches are not yet routine. Regulation, clinical validation, and real-world integration take time. Progress in medicine is rarely linear, and hype alone does not heal patients. And yet, something important is happening. AI is quietly shifting medicine from a reactive discipline toward a more anticipatory and compassionate one, where fewer patients have to go through treatments that won’t help them, and more receive therapies chosen with evidence tailored to their own biology. Innovation doesn’t have to be loud to be meaningful. Sometimes it’s careful. Sometimes it’s slow. And sometimes it’s deeply human. Curious to hear your thoughts: Where do you see AI making the most human difference in medicine? #artificialintelligence #AI #medicine #healthcare #precisioncare